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Equine herpesvirus 1 (EHV-1) mutants devoid of the open reading frames (ORFs) of either glycoprotein (g) B or M were
constructed and tested for their immunogenic potential in a murine model of EHV-1 infection. The mutant viruses were
engineered using the virulent EHV-1 strain RacL11 or the modified live vaccine strain RacH by inserting the Escherichia
coli LacZ gene into the viral ORFs. RacL11-infected mice showed signs typical of an EHV-1 infection, whereas mice infected
with the EHV-1 gB- or gM-negative mutants or with RacH did not develop disease. No difference in the pathogenic potential
of RacL11 gB- and gM-negative viruses was observed after application of either phenotypically complemented or negative
viruses. However, revertant RacL11 viruses in which the gB or gM gene had been restored caused EHV-1-related symptoms
that were indistinguishable from those induced by RacL11. Mice that had been immunized with phenotypically negative gB-
and gM-deficient EHV-1 were challenged with the RacL11 virus 25 days after immunization. Mock-immunized mice developed
EHV-1 disease and high virus loads in their lungs were observed. In contrast, mice immunized with the mutant viruses did
not exhibit EHV-1-caused disease. It was concluded (i) that deletion of either gB or gM abolished the virulence of strain
RacL11 and (ii) that immunization with gB- or gM-negative EHV-1 elicited a protective immunity that was reflected by both
virus-neutralizing antibodies and EHV-1-specific T-cells in spleens of immunized mice. q 1997 Academic Press
INTRODUCTION (Awan et al., 1990; Tewari et al., 1994; Osterrieder et al.,
1995; Stokes et al., 1996). However, the use of MLVs
Equine herpesvirus 1 (EHV-1), a member of the Alpha- has advantages over the recombinant subunit vaccines.
herpesvirinae, is the major cause of virus-induced abor- MLVs are able to induce cell-mediated immune re-
tion in equids and causes respiratory and neurological sponses, which are most likely to be responsible for
disease (Allen and Bryans, 1986). The entire DNA se- protection against disease (Allen et al., 1995; Mumford
quence of the EHV-1 strain Ab4p has been determined et al., 1995), and facilitate the expression of foreign genes
(Telford et al., 1992); however, only few genes and gene (Osterrieder et al., 1996a).
products that determine the virulence of individual strains In addition to numerous reports on the immunogenicity
have been identified. Among them are the viral thymidine of alphaherpesviruses that lack nonessential genes, in-
kinase (Cornick et al., 1990; Slater et al., 1993) and the vestigations on the immunogenic and protective capacity
product of gene 67 (IR6) (Osterrieder et al., 1996b). For of replication-deficient alphaherpesviruses that do not
control of EHV-1 infections, two different approaches are produce infectious virus progeny have been performed
followed. First, modified live vaccines (MLVs) have been during the past years. Among those are HSV-1 and HSV-2
developed, including the strain RacH (Mayr et al., 1968; mutants that lack an essential gene, the single-stranded
Hu¨bert et al., 1996), which is widely used in Europe and DNA-binding protein (Nguyen et al., 1992; Morrison and
the United States. Second, inactivated vaccines and inde- Knipe, 1994, 1996; Da Costa et al., 1997), but also glyco-
pendently expressed viral glycoproteins have been as- protein-deficient HSV-1, HSV-2, or pseudorabies virus
sessed for their immunogenic and protective potential. mutants (Heffner et al., 1993; Farrell et al., 1994; McLean
Among the glycoproteins that were expressed using re- et al., 1994; Peeters et al., 1994; Mettenleiter et al., 1995).
combinant baculoviruses are the glycoproteins (g) B, C, The aim of this study was to examine the immunoge-
D, and H, which induced partial protection against subse- nicity of EHV-1 mutant viruses that lack major constit-
quent challenge EHV-1 infection in a murine model uents of the viral envelope. To this end, mutants of two
different EHV-1 strains, the virulent RacL11 strain and
the MLV strain RacH (Mayr et al., 1968; Hu¨bert et al.,
1 To whom correspondence and reprint requests should be ad- 1996), lacking the sequences encoding for either the gB
dressed at present address: Federal Research Center for Virus Dis-
gene, which is essential for virus growth in vitro, or theeases of Animals, Institute for Molecular and Cellular Virology,
nonessential gM gene were generated. We show that theFriedrich-Loeffler-Institutes, D-17498 Insel Riems, Germany. Fax: /49-
38351-7151. E-mail: klaus.osterrieder@rie.bfav.de. engineered mutant viruses were able to elicit protective
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TABLE 1 phenotypically negative viruses, equine dermal cells (Ed-
min337) were infected with phenotypically comple-Genotypes and Phenotypes of the Engineered Viruses
mented viruses at an m.o.i. of 10 (the m.o.i.’s were deter-
Immunoprecipitationsb mined by titrations on the complementing cell lines). To
avoid contamination of phenotypically negative virus
Virus Genotypea 3F6 13B2 preparations with complemented virus, nonpenetrated
inoculum virus was inactivated after a 2-h adsorption andRacL11 RacL11 140/78/55 55/48
penetration period at 377C with citrate buffer (pH 3.0)RacH RacH 140/78/55 55/48
L11DgB RacL11/gB0::LacZ/ Negc 55/48 (Neubauer et al., 1997). Noncomplemented gB-negative
HDgB RacH/gB0::LacZ/ Neg 55/48 virions were harvested by two rounds of freeze–thawing
L11-L11gB L11DgB/gB/::LacZ0 140/78/55 55/48 at day 4 postinfection, and the virus contained in these
L11DgM RacL11/gM0::LacZ/ 140/78/55 Neg
preparations was titrated on complementing cells or non-HDgM RacH/gM0::LacZ/ 140/78/55 Neg
complementing Edmin337 cells. Plaques or single in-L11-L11gM L11DgM/gM/::LacZ0 140/78/55 55/48
fected cells (gB-negative viruses on noncomplementing
a The genotypes of the individual viruses are given. The original virus cells) were counted after Bluo-Gal staining.
used for generating the recombinant viruses is given before the slash;
the respective genotype is indicated after the slash. The genotypes Antibodies
were determined by Southern blot hybridizations using gB-, gM-, or
LacZ-specific sequences (Osterrieder et al., 1996a; Neubauer et al., Monoclonal antibodies (mabs) 3F6, 4B6, and Be/3F8,
1997). which are directed against the aminoterminal (3F6, 4B6)b Expression of gB or gM was determined by radioimmunoprecipita-
or carboxyterminal subunit of EHV-1 gB (Be/3F8) (Allention analysis of Rk13 infected-cell lysates harvested at 36 h after infec-
and Yeargan, 1987; Osterrieder et al., 1995; Neubauer ettion using anti-gB mabs 3F6, 4B6, and Be/3F8 or anti-gM mab 13B2 and
confirmed by Western blot analysis using the same mabs. Molecular al., 1997), and mab 13B2 directed against EHV-1 gM
weights of precipitated proteins are indicated in thousands. (Allen and Yeargan, 1987; Pilling et al., 1994; Osterrieder
c Neg, no reaction was obtained. et al., 1996a) were used. Mabs 3F6 and 13B2 were kindly
provided by Dr. G. P. Allen (Lexington, KY).
immune responses against EHV-1-caused disease in a Protein analyses
murine infection model.
For Western blot analysis, Edmin337 cells were in-
fected at an m.o.i. of 2 to 10. At 24 to 48 h after infection,MATERIALS AND METHODS
cell lysates were prepared (Sambrook et al., 1989), sus-
Viruses and cells pended in sample buffer (final concentration: 50 mM
Tris–Cl, pH 6.8; 3.2% sodium dodecyl sulfate (SDS); 5%The pathogenic virus strain RacL11 and its attenuated
2-mercaptoethanol; 10% glycerol), and heated at 567C forhigh-passage derivative RacH have been described
2 min. Proteins were separated by discontinuous SDS–(Mayr et al., 1968; Hu¨bert et al., 1996). The recombinant
10% polyacrylamide gel electrophoresis (Laemmli, 1970)viruses used in this study were L11DgB, L11DgM,
and transferred to nitrocellulose membranes by the semi-HDgB, and HDgM. Construction of RacL11 viruses lack-
dry method (Kyhse-Andersen, 1984), and immunoblottinging gB (L11DgB) or gM (L11DgM) has been reported
was done exactly as described (Neubauer et al., 1997).(Osterrieder et al., 1996a; Neubauer et al., 1997). The gB-
For immunoprecipitations, 1 1 106 Rk13 cells were in-and gM-negative RacH viruses (HDgB and HDgM) were
fected with the indicated viruses at an m.o.i. of 5 andconstructed by cotransfection of RacH viral DNA (1 – 2
continuously labeled with 100 mCi/ml [35S]methioninemg) and 1–10 mg plasmid pgBb/N or pgMb/ into Rk13
and [35S]cysteine (Tran-35S-label; ICN) for 36 h. Cell ly-cells exactly as described for the RacL11 mutants (Oster-
sates were prepared, and immunoprecipitations withrieder et al., 1996a; Neubauer et al., 1997). Rescuant
mabs 3F6, 4B6, Be/3F8, and 13B2 were performed asviruses from the RacL11 gB- and gM-negative mutants
described previously (Neubauer et al., 1997; Osterriederwere obtained by cotransfection of L11DgB or L11DgM
et al., 1997).viral DNA (1–2 mg) and 1–10 mg of pLP5 (harboring the
RacL11-gB ORF; Neubauer et al., 1997) or pCgM DNA
Animal experiments
(harboring the RacL11-gM ORF; Osterrieder et al., 1996a).
The resulting viruses, L11-L11gB and L11-L11gM, were Three- to four-week-old BALB/c mice (Charles River)
were divided into groups of 5 to 10 animals and infectedisolated by selection of colorless virus plaques in the
presence of Bluo-Gal. A synopsis of the generated vi- intranasally (i.n.) with different viruses. Each animal was
administered 1 1 105 plaque-forming units (PFU) in 20ruses is given in Table 1.
For immunizations, gB- or gM-negative viruses were ml in each experiment. The glycoprotein-deficient viruses
were inoculated as phenotypically complemented or non-administered either as phenotypically complemented vi-
ruses or as phenotypically negative viruses. To produce complemented viruses which were produced and titrated
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as described above. Virus titers were adjusted to 5 1 the manufacturer’s instructions. The grade of proliferation
was expressed as optical density values (OD450 nm 1 10).106 PFU/ml by ultracentrifugation and resuspension in
an adequate volume of DMEM–5% FCS. Mock infection
of mice was done using 20 ml of DMEM–5% FCS. Chal-
RESULTSlenge infections were performed 25 to 30 days after pri-
mary infection with 1 1 105 PFU RacL11 virus per mouse.
Analysis of HDgB and HDgM virusesBody weights were recorded daily, and virus titers in
lungs of inoculated mice were determined after homoge-
The absence of gB- and gM-encoding sequences innization of organs (Osterrieder et al., 1995, 1996b). Mean
HDgB and HDgM was demonstrated by Southern blotbody weights and mean virus titers of the mouse groups
analysis with labeled gB, gM, and LacZ sequences (Ost-were compared by analysis of variance, and testing of
errieder et al., 1996a; Neubauer et al., 1997). In DNAsignificances was done according to Bonferroni as de-
prepared from HDgB virions and cleaved with BamHI,scribed by Holm (1979). Lung samples were frozen in
fragments of 8.8 and 20.1 kb reacted with the gB-specificliquid nitrogen using Tissue-Tek (Miles) and serial 10-
probe, whereas only the 8.8-kb fragment reacted withmm sections were cut. b-Galactosidase activity was de-
the LacZ probe. After digestion with PstI, fragments oftermined after acetone fixation with Bluo-Gal staining
7.0 kb reacted with both probes. These data exactly cor-solution [final concentrations: 300 mg/ml Bluo-Gal (Gibco-
responded to those obtained with L11DgB, the gB-nega-BRL), 5 mM K4Fe(CN)6 , 5 mM K3Fe(CN)6 , 2 mM MgCl2 ,
tive RacL11 virus (Neubauer et al., 1997). The results0.1% Triton X-100 in PBS], and sections were counter-
obtained after Southern blot analysis of HDgM DNA alsostained with nuclear fast red (Merck). To monitor serolog-
paralleled those of L11DgM (Osterrieder et al., 1996a),ical responses, serum neutralization tests (SNT) and en-
in that fragments of 15.2 kb reacted with both the gM-zyme-linked immunosorbent assays (ELISA) were per-
specific probe and the LacZ probe after digestion of puri-formed. On the day of immunization (day 0) and on day
fied HDgM DNA with BamHI. After digestion with PstI,15 after immunization, blood samples were collected
a 13.3-kb fragment of HDgM DNA reacted with bothfrom three mice of each group by retrobulbar venipunc-
probes. From these results it was concluded that theture and sera of individual groups were pooled. The sera
Escherichia coli LacZ gene was correctly inserted intowere analyzed by SNT using 50 TCID50 RacL11 virus
the gB ORF (HDgB) or the gM ORF (HDgM), respectivelyand Rk13 cells, and by an ELISA using sucrose gradient-
(Table 1).purified RacL11 virus as the antigen (Osterrieder et al.,
To confirm the absence of intact or aberrant forms of1995).
gB in HDgB or gM in HDgM, radioimmunoprecipitation
and Western blot analyses were performed. Analysis ofLymphocyte transformation assays
RacH-infected cell lysates by immunoprecipitation with
mab 3F6, 4B6, or Be/3F8 gave the typical pattern ofFive mice each were infected i.n. (three times at 14-
EHV-1 gB in that proteins of Mr 140,000, 75,000–78,000,day intervals) with RacH, were mock-infected, or were
and 53,000–55,000 were visualized (Table 1). In addition,infected with phenotypically negative HDgB or HDgM
the gM-specific polypeptides of Mr 46,000–48,000 andviruses. EHV-1-specific lymphocyte transformation was
50,000–55,000 were detected by fluorography after pre-examined in a 5*-bromodeoxyuridine (BrdU) incorpora-
cipitation with mab 13B2. In contrast, only the gM poly-tion assay (Muir et al., 1990; Wemme et al., 1992). Lym-
peptides were present in lysates of HDgB-infected cells,phocytes were recovered from homogenized spleens on
whereas none of the gB-specific mabs specifically pre-day 25 after the last inoculation, purified by density cen-
cipitated any protein in this preparation (Table 1). Whentrifugation using Ficoll, and plated in 96-well U-bottom
a lysate of HDgM-infected cells was analyzed with theplates at a concentration of 51 104 cells/well in triplicate
same mabs, only the different forms of gB were precipi-in 100 ml RPMI 1640 medium (Biochrom) supplemented
tated with the anti-gB mabs. No reactivity was obtainedwith 5% FCS and 50 mM 2-mercaptoethanol (Sigma). One
with mab 13B2 (Table 1). Western blot analyses of in-hundred microliters of various dilutions of sucrose-gradi-
fected-cell lysates confirmed the absence of gB in HDgBent purified infectious or UV-inactivated RacH, HDgB, or
and gM in HDgM (data not shown), and it was concludedHDgM virus (m.o.i. of 0.02 to 20) was added to each
that the engineered viruses did not produce intact orwell. Mitogen-induced proliferation served as a positive
aberrant forms of the deleted glycoproteins.control. Con A (5 mg/ml)-containing medium was added
The rescuant viruses L11-L11gB and L11-L11gM wereto the splenocytes in triplicate, and cells were incubated
also analyzed by Southern and Western blot analysis.for 3 days at 377C. Twenty microliters of a 1 mM BrdU
Genotypes of the viruses did not differ from those ofsolution was added to each sample at day 3, except for
the parental RacL11 virus, and both gB and gM werethe anti-BrdU mab control, and incubated for 15 h. BrdU
expressed in cells infected with L11-L11gB and L11-incorporation was detected by a commercially available
colorimetric assay (Boehringer Mannheim) according to L11gM (Table 1).
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TABLE 2 menting cells that were virtually indistinguishable from
that of RacL11 (Table 2).Titers of Engineered Viruses on Different Host Cells
Phenotypically complemented gB- and gM-negativeVirus titer a on
EHV-1 are apathogenic for mice
Virus TCgBf TCgM Edmin337
The pathogenicity of the glycoprotein-deficient RacL11
RacL11 NDb ND 4.4 1 106 and RacH viruses was analyzed in a murine model of
RacH ND ND 5.2 1 106 EHV-1 infection. Mice were divided into groups of 10
L11DgB 3.7 1 106 ND 10 (3.2 1 104)c
animals and infected i.n. (1 1 105 PFU per mouse)HDgB 2.7 1 106 ND 10 (3.9 1 104)c
with phenotypically complemented L11DgB, L11DgM,L11-L11gB ND ND 4.7 1 106
HDgM, or HDgB viruses. Control groups included 6 miceL11DgM ND 2.9 1 106 6.3 1 104
HDgM ND 4.1 1 106 3.4 1 105 each that were infected with RacL11 or RacH or were
L11-L11gM ND ND 2.4 1 106 mock-infected with DMEM–5% FCS. Mice were moni-
tored for 11 days after infection, and the body weightsa Virus titers were determined by duplicate titrations on the indicated
of individual mice were determined daily. Additionally,cell line under a 1.25% methocellulose overlay after production of the
the behavior of the mice was observed during this timeviruses on Edmin337 cells (for titrations on Edmin337 cells), TCgM
cells (L11DgM, HDgM), or TCgBf cells (L11DgB, HDgB). Plaques were period. On days 3 and 5 after infection, 2 mice of each
visualized with methylene blue or—in the case of gB- and gM-negative group were necropsied and viral titers in lungs were
viruses—by Bluo-Gal staining.
determined. The results are summarized in Fig. 1: Miceb ND, not done.
infected with phenotypically complemented L11DgB,c In the case of gB-negative viruses plated on Edmin337 cells, no
L11DgM, HDgM, and HDgB viruses did not lose bodyplaque formation was observed at the lowest dilution (1:10). Numbers
in parentheses indicate single blue-staining cells that were visualized weight after infection and mean body weights increased
by Bluo-Gal staining. up to day 11 after infection, similar to RacH- or mock-
infected mice. In contrast, RacL11-infected mice experi-
enced a massive reduction in mean body weight which
Growth of HDgB and HDgM on different host cells was as high as 27% for individual animals (Fig. 1A).
RacL11-infected mice did not reach preinfection weights
HDgB and HDgM were analyzed for their growth char-
until the end of the observation period (day 11), and ex-
acteristics on the respective complementing cells (TCgBf
hibited clinical symptoms indicative of infection with
or TCgM) and noncomplementing Edmin337 cells. The
EHV-1 such as dyspnoea, conjunctivitis, ruffled fur, and
data are summarized in Table 2. The HDgB virus was
crouching in corners. In contrast, the mice in all other
able to produce plaques on gB-expressing TCgBf cells
groups did not show any signs of EHV-1 disease. Viral
only, but was able to infect noncomplementing cells al-
replication after infection with complemented glycopro-
though at reduced efficiency. This was demonstrated by
tein-negative viruses was assessed by virus titrations of
the presence of single infected Edmin337 cells identified
lungs that were collected on days 3 and 5 (2 mice each).
by Bluo-Gal staining (Table 2). The particle per PFU ratio
Titers were determined on Edmin337 cells (RacL11,
of noncomplemented HDgB virus preparations ranged
RacH), on TCgBf cells (L11DgB, HDgB), or on TCgM
from 4200 to 8300 in four independent experiments, and
cells (L11DgM, HDgM). Infectious virus could be recov-
exceeded those of HDgB viruses prepared on comple-
ered from lungs of RacL11-infected animals on both day
menting cells (particle per PFU ratio of 39 to 96) by 86-
3 and day 5 p.i. (Fig. 1B). In contrast, no infectious virus
to 108-fold. The behavior of the HDgB virus therefore
could be recovered in L11DgB- and HDgB-infected ani-
closely resembled its counterpart L11DgB that was de-
mals, and in L11DgM- and HDgM-infected animals in-
rived from the RacL11 virus (Neubauer et al., 1997).
fectious virus was recovered on day 3 p.i. only. In addi-
However, when the gM-negative RacH virus, HDgM,
tion, the virus titers after infection with the gB- and gM-
was investigated, titers on noncomplementing cells were
negative viruses were significantly reduced (P  0.05)
reduced by only approximately 10-fold compared with the
on both day 3 and day 5 p.i. (Holm, 1979) when compared
parental RacH virus or with the titers on complementing
with titers after infection with the RacL11 virus (Fig. 1B).
TCgM cells (Table 2). Hence, HDgM titers on noncom-
plementing cells were approximately 10-fold higher than Immunogenicity of the engineered gB- and gM-
those observed for L11DgM (Osterrieder et al., 1996a). negative EHV-1 mutants
In addition, the syncytial phenotype of the RacH virus
(Neubauer et al., 1997) was even more pronounced in Preliminary experiments suggested that glycoprotein-
deficient EHV-1 might be candidates for efficient markerthe absence of gM and no reduction in plaque size as
described for the L11DgM virus mutant (Osterrieder et vaccines, because mice that had been infected with com-
plemented L11DgB, L11DgM, HDgB, or HDgM wereal., 1996a) could be detected. The rescuant viruses (L11-
L11gB and L11-L11gM) exhibited titers on noncomple- protected against challenge with the RacL11 virus (data
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the infection experiments are summarized as follows
(Fig. 2A): (i) Mice infected with RacL11 or the rescuant
viruses L11-L11gB and L11-L11gM experienced a mas-
sive decrease in mean body weight. A 21% or greater
reduction in body weight was observed for individual
mice on days 2 and 3 after infection in the respective
groups. In addition, up to 2 mice of each group died at
day 3 p.i. in this experiment (RacL11, 2; L11-L11gB, 0;
L11-L11gM, 1). Mice were monitored for 11 days but did
not reach preinfection weights and showed clinical signs
FIG. 1. Infection of mice with phenotypically complemented gB- and
gM-negative viruses. (A) Mean body weights of mice infected with
complemented L11DgB, L11DgM, HDgB, and HDgM (10 mice each)
viruses. Controls included mice that were mock-infected or infected
with RacL11 or RacH (6 mice each). Mean body weight on the day of
infection (day 0) was set at 100%. Individual mice were weighed on
days 1 to 11 after infection. Means are expressed as a percentage of
the day 0 weights. Different numbers of mice were weighed on days
1 to 3 (6 to 10 mice), days 4 and 5 (4 to 8 mice), and days 6 to 11 (2
to 6 mice) Standard deviations ranged from 1.9 to 3.8% and are not
shown. The difference in mean body weight of RacL11-infected mice
compared with all other groups was highly statistically significant (P
 0.001) on days 2 to 9 after infection (Holm, 1979). (B) Virus titers in
lungs of individual mice at day 3 (closed symbols) and 5 (open symbols)
after infection. Individual titers are given. Virus titers were determined
on Edmin337 cells (RacL11, RacH), on TCgBf cells (L11DgB, HDgB),
or on TCgM cells (L11DgM, HDgM).
FIG. 2. Infection of mice with phenotypically negative gB- and gM-not shown). Therefore, the next series of experiments
deficient viruses. (A) Mean body weights of mice infected with RacL11,
addressed the immunogenicity of phenotypically nega- RacH, and the gB- and gM-negative mutants and mock-infected mice.
tive glycoprotein-deficient viruses. Groups of 10 mice Mean body weights were determined as described for Fig. 1. Standard
deviations ranged from 0.9 to 2.4% and are not shown. The differencewere infected i.n. with 1 1 105 PFU of the recombinant
in mean body weights of RacL11-, L11-L11gB-, and L11-L11gM-infectedvirus L11DgB, L11DgM, HDgB, or HDgM after produc-
mice, compared with all other groups, was highly statistically significanttion on Edmin337 cells. These PFUs corresponded to
(P 0.001) on days 2 to 8 after infection. (B) Serum-neutralizing (circles)
approximately 5 1 107 (HDgM), 1 1 108 (L11DgM), or 1 and ELISA antibody (quadrangles) titers in immunized mice. Reciprocal1 109 virus particles (L11DgB, HDgB). Control groups values of serum titers are given. The titers were determined from a
pool of three sera per mouse group which were prepared on day 0included mice infected i.n. with RacL11, RacH, and rescu-
(day of immunization: open symbols) and from the same mice on dayant RacL11 viruses, in which the deleted gB or gM gene
15 after immunization (closed symbols). Serum neutralizing titers reflecthad been reinserted (L11-L11gB and L11-L11gM). In the
the serum dilution with complete protection in all three wells. ELISA
case of these viruses, approximately 1 1 107 particles antibody titers were judged positive when exceeding counts of control
were administered to each mouse. The mice were moni- sera from mock-infected mice at the 1:10 dilution (mean 0.054 { 0.013)
by 3 standard deviations.tored after infection as described above. The results of
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of infection (see above). (ii) In contrast, mice infected with the phenotypically negative recombinant viruses or
the RacL11 and RacH viruses or after mock infection,with L11DgB, L11DgM, HDgB, HDgM, or RacH did not
exhibit clinical symptoms or body weight losses at any mice were infected i.n. with 1.0 1 105 PFU of the patho-
genic RacL11 strain. The results of these experimentstime p.i. Rather, the mean body weights gradually in-
creased in these groups confirming the results obtained were as follows. In none of the previously infected mice
was a reduction in body weight observed upon challengewith the phenotypically complemented glycoprotein-defi-
cient viruses. (iii) The effects of the recombinant viruses infection. The mean body weights remained constant
throughout the observation period in groups infected pre-on the mice were similar to those after mock infection,
which was performed with DMEM–5% FCS alone. The viously with RacL11, RacH, and phenotypically negative
L11DgB, L11DgM, HDgB, or HDgM (Fig. 4A). In con-differences in mean body weights among the RacL11,
L11-L11gB, and L11-L11gM mouse groups, compared trast, mock-immunized mice developed a reduction in
mean body weight from day 2 to 7 after infection (Fig.with all other groups, were highly statistically significant
(P  0.001) from day 2 to 8 after infection. 4A) that was highly statistically significant (P  0.001)
and exhibited clinical signs typical of the RacL11 infec-To monitor serological responses of the immunized
mice, SNT and ELISAs were performed with pooled sera tion. To investigate viral replication in the lungs of chal-
lenged mice, four mice from each group were subjectedthat were obtained from three mice of each group on
the day of immunization (day 0) and on day 15 after to postmortem examination on day 3 after infection. Viral
titers in the lungs of mock-immunized mice were as highimmunization. EHV-1-specific antibody responses could
be detected after immunization with all viruses tested, as 4.6 1 103 PFU per lung (mean 2.4 1 103) (Fig. 4B). In
contrast, virus titers of immunized mice were below 5.0but were absent in mock-infected mice (Fig. 2B). The
neutralizing antibody titers in mice immunized with the 1 101 PFU per lung in all cases and, in approximately
50% of all immunized animals, no virus was recoveredrecombinant viruses ranged from 1:2 to 1:16, and the
ELISA titers ranged from 1:160 to 1:640 at day 15 after from the lungs at day 3 after infection (Fig. 4B). Statistical
analyses demonstrated a significant (P 0.05) reductioninfection (Fig. 2B). Neutralizing antibody titers of 1:2
and ELISA antibody titers of 1:10 were observed in all of the virus titers on day 3 in all previously immunized
mice compared with mock-immunized mice. It was con-groups on the day of infection (Fig. 2B).
To document viral replication in lungs of mice infected cluded that a single immunization with phenotypically
negative L11DgB, L11DgM, HDgB, or HDgM viruseswith noncomplemented L11DgB, L11DgM, HDgB, or
HDgM, cryosections of lungs were stained with Bluo- provided protection against EHV-1-caused disease after
challenge infection in a murine model although majorGal on days 1 to 8 p.i. Virus replication in mouse lungs
could be demonstrated in that single blue-staining cells envelope glycoproteins had been deleted and the recom-
binant viruses are impaired in replication (Allen and Year-(L11DgB, HDgB) or foci of blue-staining cells (L11DgM,
HDgM) were observed in the bronchi, bronchioli, and gan, 1987; Pilling et al., 1994; Osterrieder et al., 1996a;
Neubauer et al., 1997).alveolar cells from day 1 to 5 p.i. (Fig. 3; data are shown
for HDgB and HDgM on day 4 p.i.). In the case of
L11DgB- and HDgB-infected mice, the number of b-ga- Lymphocyte transformation after immunization of
lactosidase-expressing cells remained virtually constant mice with HDgB and HDgM
from day 2 to day 8 p.i., indicating that no infectious gB-
negative virus was produced in the murine lungs. From The last series of experiments addressed the induction
of cell-mediated immune responses in mice immunizedthe results and those obtained after infection of mice
with phenotypically complemented glycoprotein-deficient with phenotypically negative recombinant viruses. To de-
termine lymphocyte transformation, a BrdU incorporationEHV-1, it was concluded that the deletion of gB or gM
in the pathogenic RacL11 strain completely abolished assay was performed. BALB/c mice were infected i.n.
with phenotypically negative HDgB or HDgM or withRacL11 virulence in a murine model, but that infection
occurred as reflected by the presence of infected target RacH virus or were mock-infected (five animals per
group). At day 25 after the third inoculation, splenocytescells and EHV-1-specific antibodies. Because the rescu-
ant viruses L11-L11gB and L11-L11gM were virtually in- were harvested from pooled spleens of each group and
seeded into 96-well plates. Cells were pulsed with puri-distinguishable from the parental RacL11 virus in the
infection experiments, the lack of virulence of L11DgB fied infectious or UV-irradiated RacH virus (0.02 to 20
PFU per cell). The results are summarized as follows (Fig.and L11DgM was due to the gene deletions. As ex-
pected, the gB- and gM-negative RacH viruses (HDgB 5). Splenocytes recovered from RacH-immunized animals
exhibited the highest incorporation of BrdU after a 72-hand HDgM), as the parental RacH virus, did not induce
EHV-1 disease in infected mice. incubation period with purified and infectious RacH virus
(m.o.i. of 0.02 and 0.2) (Fig. 5A). The higher m.o.i.’s (2The protective potential of each phenotypically nega-
tive glycoprotein-deficient EHV-1 against challenge infec- and 20) had a toxic effect on the splenocytes. A similar
incorporation of BrdU was also observed in splenocytestion was examined. Twenty-five days after initial infection
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FIG. 3. Photographs of 10-mm sections of frozen and fixed lungs recovered from (A) HDgB- or (B) HDgM-immunized mice and stained with Bluo-
Gal. Sections were counterstained with nuclear fast red and analyzed in a Zeiss Axiovert 25 microscope [Magnification: 4001 (A) and 1001 (B)].
that were recovered from mice immunized with HDgB sive stimulation could be documented at an m.o.i. of 0.2,
and no transformation was observed using an m.o.i. ofand HDgM (Fig. 5A), whereas stimulation of splenocytes
from mock-immunized mice did not show significant 0.02 of RacH virus (Fig. 5B). Con A stimulation of spleno-
cytes harvested from the different mouse groups led totransformation at either m.o.i. (Fig. 5A). Stimulation of
splenocytes with inactivated RacH virus gave results sim- optical density values of 15.4 to 17.9 with standard devia-
tions ranging from 1.2 to 2.2. From these results we con-ilar to those observed after live virus stimulation of cells
obtained from RacH- or HDgM-immunized animals (Fig. cluded that immunization with phenotypically negative
glycoprotein-deficient RacH viruses led to the presence5B). However, stimulation of spleen cells from HDgB-
immunized mice with inactivated RacH virus led to a of EHV-1-specific T-cells in spleens of immunized mice.
It is noteworthy that no significant difference betweendecreased incorporation of BrdU such that a less exten-
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In particular, the protective potential of RacH-derived gly-
coprotein-deficient mutants was addressed, because the
RacH virus is a widely used MLV strain. In addition, the
apathogenicity of RacH for equids and laboratory animals
is well defined and was shown to be due to the absence
of the gene 67 (IR6) product (Mayr et al., 1968; Hu¨bert et
al., 1996; Osterrieder et al., 1996b).
It is documented that deletion of either gB or gM in
the pathogenic EHV-1 strain RacL11 not only affects the
viruses’ growth characteristics in vitro, but also abolishes
their pathogenicity in vivo. Loss of pathogenicity was
observed after administration of both phenotypically
complemented or noncomplemented gB- or gM-negative
RacL11 viruses. From these results it can be concluded
that the reduced pathogenicity is due to a restriction in
viral replication that occurs after the initial infection
which is taking place as demonstrated by the presence
of blue-staining cells in lungs of mice after addition of
the chromogenic substrate Bluo-Gal. The observation of
the avirulence of glycoprotein-deficient EHV-1 mutants
reported in this study concurs with reports on the re-
duced virulence of a herpes simplex virus 1 gM-negative
FIG. 4. RacL11 challenge infection of mice immunized with different
mutant constructs. (A) Mean body weights of immunized and chal-
lenged mice. The values for each group were determined as described
for Fig. 1. Because some mice died after the primary inoculation and
some mice were necropsied, more mice were weighed on days 1 to
3 (8 to 10 mice per group) than on days 4 to 11 (4 to 6 mice per group).
The standard deviations ranged from 1.1 to 3.4% and are not shown. The
differences in mean body weight of mock-infected mice after challenge
infection, compared with those of the immunized groups, were highly
statistically significant (P  0.001) from day 2 to 7 after challenge
infection (Holm, 1979). (B) Virus load in lungs of immunized mice at
day 3 after challenge infection. Shown are the individual viral titers per
lung of 4 mice as determined by titration on Edmin337 cells. In mice
immunized with L11DgB and L11DgM, no virus could be detected in
any of the isolated lungs after challenge. The difference in mean virus
titers (arithmetic means) between mock-immunized mice and those
immunized previously with the different viruses was statistically signifi-
cant (P  0.05) (Holm, 1979).
RacH-immunized animals and mice immunized with the
gB- or gM-negative RacH after stimulation with live virus
could be observed. Similarly, stimulation of isolated
splenocytes with either HDgM or HDgB did not reveal
FIG. 5. Lymphocyte transformation assay. Pooled splenocytes from
marked differences between RacH-, HDgM-, or HDgB- five mice immunized with RacH, HDgB, or HDgM or from mock-immu-
immunized animals (data not shown). nized mice were pulsed with (A) live or (B) inactivated RacH virus.
Different virus concentrations of 0.2 (black bars) or 0.02 PFU per cell
(white bars) were used for stimulation. Stimulation values are given as
DISCUSSION optical densities (OD450 nm 1 10) that were determined using a commer-
cial BrdU incorporation assay. Means of three independent experi-
This study describes the testing of a panel of recombi- ments are given and standard deviations are indicated. Optical densi-
nant EHV-1 that lacked either gB or gM, for immunogenic- ties of Con A-stimulated splenocytes ranged between 15.4 and 17.9
with standard deviations between 1.2 and 2.2.ity and virulence in a murine model of EHV-1 infection.
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mutant in a murine model (MacLean et al., 1993) and a caused disease (Mumford et al., 1995). In addition, the
presence of EHV-1-specific cytotoxic, predominantlyrecent report on an EHV-1 gene 71-negative mutant that
no longer expresses EHV-1 gp1/2 (Marshall et al., 1997). CD8/ T-lymphocytes in horses infected with EHV-1 could
be demonstrated (Allen et al., 1995). Further studies willSince the behavior of EHV-1 strains in BALB/c mice cor-
relates with that of individual viruses in the natural host therefore concentrate on the cellular immune responses
upon immunization with the glycoprotein-deficient EHV-(Mayr et al., 1968; vanWoensel et al., 1995; Colle et al.,
1996; Hu¨bert et al., 1996; Matsumura et al., 1996), a re- 1, and it will be investigated whether cytotoxic T-cells
are induced by the different virus mutants. The fact thatduced virulence of L11DgB and L11DgM in horses is
likely. Immunization of mice with L11DgB and L11DgM, the observed T-cell responses are at least partially di-
rected against proteins other than gB or gM, which repre-and also with HDgB and HDgM, which represent gB- or
gM-negative mutants of the MLV RacH, conferred protec- sent late viral gene products (Sullivan et al., 1989; Oster-
rieder et al., 1997), might indicate the importance of earlytion against subsequent EHV-1 challenge infection after
a single administration. It must be noted that approxi- or immediate-early EHV-1 gene products for T-cell reac-
tivity. In addition, the reduced reactivity of splencocytesmately 108 (HDgM, L11DgM) or 109 (HDgB, L11DgB)
virus particles were administered to the mice in the case obtained from HDgB-infected animals suggests that gB
is a target of the cellular immune response after EHV-1of phenotypically negative virus mutants, whereas RacH
and RacL11 preparations contained approximately 107 infection.
In summary, the protective capacity of gB- and gM-particles. Immunization with lower live virus doses (107
HDgB or L11DgB virus particles, i.e., 1 1 103 PFU), as negative EHV-1 mutants could be demonstrated in a mu-
rine infection model. The features of especially the gM-well as immunization with UV-irradiated gB- or gM-nega-
tive RacH viruses (corresponding to 1 1 105 PFU), how- negative RacH virus are important in our attempts to
modify this EHV-1 strain such that a biologically safe butever, did not induce protective immunity in mice. In addi-
tion, no b-galactosidase-expressing cells in mouse lungs efficient MLV is generated. Further studies will focus
on the testing of the gM-negative RacH virus in horses,could be demonstrated after the application of lower
doses of live HDgB or L11DgB (data not shown). For because HDgM could serve as a marker vaccine and
as a vehicle for the expression of foreign genes.the induction of an immune response in mice that is
elicited by gB-negative viruses, one round of replication
of the viruses in the target tissue appears to be crucial ACKNOWLEDGMENTS
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